Share
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers, providers and other stakeholders to the technologies than ever before.
As the sector continues to find its footing, new players small and large will look to throw their hat into the ring. By doing so, they ll come to a crossroad that s very familiar to those with a background in the pharmaceuticals industry: whether to develop their new product in house or to in-license and release a promising candidate from academia or another company.